Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Pierre, Fender"'
Autor:
Jean-François Bergmann, Michel Andrejak, Jean-Pierre Bader, Marion Bamberger, Pascal Bilbault, Régis Bordet, Agnès Brouard, Anne Burstin, Alain Castaigne, Anne Castot, Alain Coulomb, Muriel Dahan, Frédéric DeBels, Corinne Duguay, Nathalie Dumarcet, Pierre Fender, Christian Funck Brentano, Isa-belle Giri, Pascale Jolliet, Murielle Jousselon Pautrot, Florence Leclerc, Patricia Le Gonidec, Patricia Maillere, François Meyer, Thierry Moreau Defarges, Olivier Obrecht, Gilles Paintaud, Nicole Petitcollot, Marc Samama, Julia Sauterey, Pierre Schiavi, Philippe Tcheng, Patrick Villani, Monique Weber, Nadine Weisslinger Darmon, Myriam Zylberman
Publikováno v:
Therapies. 63:267-273
Resume Le bon usage des medicaments peut etre defini simplement comme l’utilisation du bon medicament, a la bonne dose, pendant la duree necessaire, pour un patient donne qui le tolere correctement. Il est impossible, etant donne le nombre de medic
Autor:
Didier Guillemot, Georges France, Pierre Fender, J.-M. Alexandre, O. Amede-Manesme, J.-P. Bader, M. Bouhassira, B. Calles, A. Castaigne, M. Chauvenet, B. Diquet, I. Giri, F. Ichou, P. Jolliet, J.-M. Joubert, J.-P. Lehner, M. Lièvre, H. Mathiex-Fortunet, M. Marty, F. Meyer, J. Micallef, M. Pigeon, B. Rouveix, F. Zannad
Publikováno v:
Therapies. 60:359-362
Resume Des lors qu’un nouveau medicament est susceptible d’etre commercialise, la question de l’evaluation du progres therapeutique se pose en deux temps. Tout d’abord quelle est la quantite de progres therapeutique attendu ? Ce premier temps
Autor:
Didier Guillemot, Georges France, Pierre Fender, J.-M. Alexandre, O. Amede-Manesme, J.-P. Bader, M. Bouhassira, B. Calles, A. Castaigne, M. Chauvenet, B. Diquet, I. Giri, F. Ichou, P. Jolliet, J.-M. Joubert, J.-P. Lehner, M. Lièvre, H. Mathiex-Fortunet, M. Marty, F. Meyer, J. Micallef, M. Pigeon, B. Rouveix, F. Zannad
Publikováno v:
Therapies. 60:363-366
When a candidate drug is likely to become available to prescribers and healthcare policy makers, evaluation of therapeutic progress moves forward in two stages. First, the level of expected therapeutic progress must be established. This first stage r
Autor:
Soizic Courcier-Duplantier, Bruno Falissard, Pierre Fender, B. Arnould, B. Avouac, O. Chassany, B. Hamelin, G. Lapeyre, P. Lendresse, A. Leplège, M. Lièvre, H. Mathiex-Fortunet, G. Paintaud, M. Pigeon, A. Puech, R. Samoyeau, A. Spriet, G. Steinberg, C. Vilain
Publikováno v:
Therapies. 58:267-273
The use of subjective outcome measures for assessing drug efficacy varies according to the disease in question. Subjective outcome measures used to complement an objective outcome measure can clearly claim the status of a main outcome measure. The va
Autor:
Soizic Courcier-Duplantier, Bruno Falissard, Pierre Fender, B. Arnould, B. Avouac, O. Chassany, B. Hamelin, G. Lapeyre, P. Lendresse, A. Leplège, M. Lièvre, H. Mathiex-Fortunet, G. Paintaud, M. Pigeon, A. Puech, R. Samoyeau, A. Spriet, G. Steinberg, C. Vilain
Publikováno v:
Therapies. 58:259-265
L'utilisation de criteres subjectifs d'evaluation de l'efficacite est variable selon les pathologies. Les criteres subjectifs utilises en complement de criteres objectifs peuvent tout a fait pretendre au statut de critere principal d'efficacite. La v
Autor:
Jean-François Bergmann, Michel Andrejak, Jean-Pierre Bader, Marion Bamberger, Pascal Bilbault, Régis Bordet, Agnès Brouard, Anne Burstin, Alain Castaigne, Anne Castot, Alain Coulomb, Muriel Dahan, Frédéric DeBels, Corinne Duguay, Nathalie Dumarcet, Pierre Fender, Christian Funck Brentano, Isa-belle Giri, Pascale Jolliet, Murielle Jousselon Pautrot, Florence Leclerc, Patricia Le Gonidec, Patricia Maillere, François Meyer, Thierry Moreau Defarges, Olivier Obrecht, Gilles Paintaud, Nicole Petitcollot, Marc Samama, Julia Sauterey, Pierre Schiavi, Philippe Tcheng, Patrick Villani, Monique Weber, Nadine Weisslinger Darmon, Myriam Zylberman
Publikováno v:
Therapie. 63(4)
Proper use of drugs can be defined as the use of the right product, in a correct dosage, during an adequate length of time, for a given patient and provided he has no serious side effects. It is virtually impossible, with such a number of drugs, such
Autor:
Françoise, Macron-Noguès, Michel, Vernay, Eric, Ekong, Bénédicte, Thiard, Benoît, Salanave, Pierre, Fender, Hubert, Allemand
Publikováno v:
Nephrologietherapeutique. 1(6)
Epidemiologic data on end-stage renal disease (ESRD) treated with renal dialysis remain sparse and incomplete in France because there is no national registry of dialysis patients. The aim of this study was to determine the characteristics (age, gende
Autor:
Jean-Baptiste Ricco, Olivier Goëau-Brissonnière, Marie-Hélène Rodde-Dunet, Michel Marty, Pierre Fender, Hubert Allemand, Andrew Corsini
Publikováno v:
Journal of Vascular Surgery. 39(6)
Autor:
Philippe Ricordeau, Pierre Durieux, Alain Weill, Gilles Chatellier, Nathalie Vallier, Alvine Bissery, Pierre Fender, Hubert Allemand
Publikováno v:
International Journal of Technology Assessment in Health Care; Dec2003, Vol. 19 Issue 4, p705-710, 6p